UHN to use Ventripoint heart analysis system

TORONTO – Ventripoint Diagnostics Ltd. is pleased to announce that the company’s proprietary VMS+3.0 whole-heart analysis system has been installed at the Peter Munk Cardiac Center (PMCC) in Toronto. PMCC is the largest cardiac centre in Canada and resides in the University Hospital Network’s (UHN) Toronto General Hospital.

This is the 5th hospital in Canada to adopt the new VMS+3.0 for assessing heart function in all four chambers of the heart.

Dr. John Granton (pictured), division head of Respirology, UHN, and lead of the Pulmonary Hypertension Program (PHP) stated: “This will help the PHP and the Congenital Heart Disease program manage, and conduct future research in, patients with right heart failure.”

“Just as it is PMCC’s mission to use the best equipment to optimize patient care, it has always been the company’s mission to create “best-in-breed” equipment to assist clinicians and medical personnel in a myriad of clinical settings to accurately assess heart function. We feel incredibly privileged to have this world-leading hospital adopt our system,” said Dr. George Adams, executive-chairman of Ventripoint.

The company has installed three VMS+3.0 whole heart analysis systems in three top-rated hospitals in the last six weeks. The company has delivered 10 VMS+3.0 systems to date and expects to install units in additional leading cardiac centres before the end of the year.

Ventripoint estimates that 40,000 VMS+3.0 units would be required based on standard-of-care guidelines to effectively diagnose, monitor and manage the health of patients with congenital heart disease, pulmonary hypertension and those suffering cardiotoxicity due to chemotherapy.

About the Peter Munk Cardiac Centre
Peter Munk Cardiac Centre is part of the University Health Network (UHN) and is located at the Toronto General Hospital in Toronto, Ontario, Canada. This cardiac centre is a world leader in the diagnosis, care and treatment of cardiovascular disease.

About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.